Share

Save

Study of Ribociclib and Everolimus in HGG and DIPG

PHASE2RECRUITING

The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target. The main question the study aims to answer is whether the combination of ribociclib and everolimus can prolong the life of patients diagnosed with HGG, including DIPG.

info
Simpliy with AI

Study details:

This is a multicenter, international, phase II study of post-radiotherapy (RT) combination of ribociclib and everolimus to treat pediatric, adolescent, and young adult patients newly diagnosed with HGG and DIPG that harbor alterations of the cell cycle and/or PI3K/mTOR pathways to assess treatment efficacy (Part 2). The study will include a feasibility cohort (Part 1) to identify the dose of ribociclib PfOS (Powder for Oral Suspension) that is safe and tolerable in combination with everolimus. Efficacy for Part 2 study will be defined by progression-free survival (PFS; HGG \[stratum A\]) and Overall Survival (OS; DIPG \[stratum B\]), with key longitudinal biomarker correlatives.

Outcomes among patients with primary thalamic, spinal cord, and/or secondary (radiation related) HGG (strata C) will be descriptively analyzed. Objective radiographic response rates and agent-specific toxicities will also be assessed, with a feasibility cohort to determine the recommended phase II dose (RP2D) of the combination of ribociclib and everolimus in patients with metastatic disease who received upfront craniospinal irradiation (stratum D). Protocol therapy with the maintenance combination of ribociclib and everolimus must begin no later than 35 calendar days post-completion of RT.

The earliest patients can begin protocol treatment is 28 calendar days post-completion of RT. Each cycle will be 28 days in duration and treatment can continue up to a total of 26 cycles. Ribociclib will be given orally once daily for 3 weeks (days 1-21), with one week off.

Everolimus will be given orally daily continuously (days 1-28).

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Inclusion criteria already met to enroll on TarGeT-SCR (central molecular and histopathologic screening) based on:
  • Exclusion criteria

  • Pregnant or Breast-Feeding Pregnant or breast-feeding women will not be entered on this study due to known potential risks of fetal and teratogenic adverse events as seen in animal/human studies.
  • Concomitant Medications: Patients who are currently receiving another investigational drug are not eligible. Patients who are currently receiving other anti-cancer agents are not eligible, with the exception of temozolomide given concurrently with RT only.
  • Patients who have an uncontrolled infection are not eligible.
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.
  • Patients with known clinically significant active malabsorption syndrome or other condition that could affect absorption are not eligible.
  • Patients with prior or ongoing clinically significant medical or psychiatric condition that, in the investigator's opinion, could affect the safety of the subject, or could impair the assessment of study results are not eligible.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 12 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2024-08-22

    Primary completion: 2028-08-28

    Study completion finish: 2034-08-28

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE2

    trial

    Trial ID

    NCT05843253

    Intervention or treatment

    DRUG: Ribociclib

    DRUG: Everolimus

    Conditions

    • High Grade Glioma
    • Diffuse Intrinsic Pontine Glioma
    • Anaplastic Astrocytoma
    • Glioblastoma
    • Glioblastoma Multiforme
    • Diffuse Midline Glioma, H3 K27M-Mutant
    • Metastatic Brain Tumor
    • WHO Grade III Glioma
    • WHO Grade IV Glioma
    Image related to High Grade Glioma
    • Condition: High Grade Glioma, Diffuse Intrinsic Pontine Glioma and more

    • DRUG: Ribociclib and other drugs

    • Randwick, New South Wales, Australia and more

    • Sponsor: Nationwide Children's Hospital

    Find a site

    Closest Location:

    Sydney Children's Hospital

    Research sites nearby

    Select from list below to view details:

    • Sydney Children's Hospital

      Randwick, New South Wales, Australia

    • Queensland Children's Hospital

      South Brisbane, Queensland, Australia

    • Perth Children's Hospital

      Perth, Western Australia, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Stratum A (n=40)
    • Patients with localized, intracranial, non-pontine, and non-thalamic HGG (who do not meet criteria for strata B, C, or D).
    DRUG: Ribociclib
    • Ribociclib PO qd on days 1-21
    EXPERIMENTAL: Stratum B (n=40)
    • Patients with DIPG, defined as a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, with histopathology consistent with diffuse WHO grade 2-4 glioma (e.g., diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, H3K27-altered diffuse midline glioma).
    DRUG: Ribociclib
    • Ribociclib PO qd on days 1-21
    EXPERIMENTAL: Stratum C (n=6-12)
    • Patients with primary thalamic, spinal cord, and/or secondary (radiation-related) HGG.
    DRUG: Ribociclib
    • Ribociclib PO qd on days 1-21
    EXPERIMENTAL: Stratum D (n=6-12)
    • Patients with metastatic/disseminated HGG, multifocal HGG, and/or gliomatosis cerebri who received craniospinal irradiation.
    DRUG: Ribociclib
    • Ribociclib PO qd on days 1-21

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Progression-Free Survival (PFS) in HGG (Part 2, Stratum A)To assess the efficacy of ribociclib and everolimus in pediatric and young adult patients newly diagnosed with HGG by estimating the distribution of PFS compared to molecularly-stratified and matched historical controls.From date on treatment until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up to 60 months
    Overall Survival (OS) in DIPG (Part 2, Stratum B)To assess the efficacy of ribociclib and everolimus in pediatric and young adult patients newly diagnosed with DIPG by estimating the distribution of OS compared to molecularly-stratified and matched historical controls.From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
    Establish MTD and RP2D of ribociclib and everolimus (Part 2, Stratum D)To identify the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of the combination of ribociclib and everolimus given to patients with metastatic HGG who have received craniospinal irradiation CSI.Completion of Cycle 1 (28 days)
    Number of participants with ribociclib and everolimus-related adverse events as assessed by CTCAE v5.0 (Part 1- initial feasibility study)Identify the safe dose of ribociclib powder for oral solution (PfOS) formulation in combination with everolimus that is feasible in pediatric patients with newly-diagnosed HGG, including DIPG, with cell cycle and/or PI3K/mTOR pathway alterations. This will be achieved by calculating the number of participants with, as well as frequency and severity of, ribociclib and everolimus-related Adverse Events as assessed by CTCAE v5.0 in the first 6-12 patients enrolledCompletion of Cycle 1 (28 days)

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Overall Survival in HGGDetermine distribution of OS for pediatric and young adult patients newly-diagnosed with HGG which harbor cell cycle and/or PI3K/mTOR pathway alterations treated with post-RT ribociclib and everolimus.From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
    Objective Response Rate (ORR) in HGGEvaluate the radiographic objective response rate (ORR) defined as complete response (CR) + partial response (PR) in pediatric and young adult patients newly diagnosed with HGG treated with the combination of ribociclib and everolimus.From Day 1 of protocol treatment through 30 days following end of protocol treatment
    Objective Response Rate (ORR) in DIPGEvaluate the radiographic objective response rate (ORR) defined as complete response (CR) + partial response (PR) in pediatric and young adult patients newly diagnosed with DIPG treated with the combination of ribociclib and everolimus.From Day 1 of protocol treatment through 30 days following end of protocol treatment
    Number of participants with ribociclib and everolimus-related adverse events as assessed by CTCAE v5.0Assess and further characterize the safety and toxicity of post-RT combination of ribociclib and everolimus in pediatric and young adult patients newly diagnosed with HGG, including DIPG. This will be achieved by calculating the number of participants with, as well as frequency and severity of, ribociclib and everolimus-related Adverse Events as assessed by CTCAE v5.0.From Day 1 of protocol treatment through 30 days following end of protocol treatment
    Evaluate Health-Related Quality of Life OutcomesEvaluate health-related quality of life outcomes of pediatric and young adult patients newly-diagnosed with HGG, including DIPG, treated with combination of ribociclib and everolimus, by patient and/or parent reporting at key timepoints in therapy using the patient reported outcomes measurement information system (PROMIS) survey.At the end of Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 (each cycle is 28 days)

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: Study of Ribociclib and Everolimus in HGG and DIPG

    Other trails to consider

    Top searched conditions